Metagenomi, Inc. Common Stock (NASDAQ:MGX) — Market Cap & Net Worth
Market Cap & Net Worth: Metagenomi, Inc. Common Stock (MGX)
Metagenomi, Inc. Common Stock (NASDAQ:MGX) has a market capitalization of $42.69 Million ($42.69 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #22586 globally and #4983 in its home market, demonstrating a -1.74% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Metagenomi, Inc. Common Stock's stock price $1.13 by its total outstanding shares 37777105 (37.78 Million). Also see Metagenomi, Inc. Common Stock (MGX) total assets for a full breakdown of the balance sheet.
Metagenomi, Inc. Common Stock Market Cap History: 2024 to 2026
Metagenomi, Inc. Common Stock's market capitalization history from 2024 to 2026. Data shows change from $132.60 Million to $42.69 Million (-62.89% CAGR). Also see Metagenomi, Inc. Common Stock cash conversion from operations for how efficiently the company converts equity into cash flow.
Index Memberships
Metagenomi, Inc. Common Stock is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #646 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #2139 of 3165 |
Weight: Metagenomi, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Metagenomi, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Metagenomi, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Metagenomi, Inc. Common Stock share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
2.43x
Metagenomi, Inc. Common Stock's market cap is 2.43 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $132.60 Million | $52.30 Million | -$78.06 Million | 2.54x | N/A |
| 2025 | $61.20 Million | $25.21 Million | -$87.87 Million | 2.43x | N/A |
Competitor Companies of MGX by Market Capitalization
Companies near Metagenomi, Inc. Common Stock in the global market cap rankings as of September 18, 2026. Review Metagenomi, Inc. Common Stock (MGX) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Metagenomi, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Metagenomi, Inc. Common Stock Historical Marketcap From 2024 to 2026
Between 2024 and today, Metagenomi, Inc. Common Stock's market cap moved from $132.60 Million to $ 42.69 Million, with a yearly change of -62.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $42.69 Million | -30.25% |
| 2025 | $61.20 Million | -53.85% |
| 2024 | $132.60 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Metagenomi, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $42.69 Million USD |
| MoneyControl | $42.69 Million USD |
| MarketWatch | $42.69 Million USD |
| marketcap.company | $42.69 Million USD |
| Reuters | $42.69 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Metagenomi, Inc. Common Stock
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for … Read more